David Bautz

James Molloy

- Qualigen Therapeutics, Inc. (the "Company") entered into an Amended and Restated Secured Demand Promissory Note (the "Amended Note") with Marizyme, Inc. on **August 21, 2025**.  **[1460702_0001641172-25-025702_form8-k.htm:1]** 
- The Amended Note has a principal balance of **$4,451,462.18**, which includes the outstanding balance and accrued interest from a prior note, plus an additional advance of **$216,000** made by Qualigen to Marizyme.  **[1460702_0001641172-25-025702_ex10-1.htm:0]** **[1460702_0001641172-25-025702_form8-k.htm:1]** **[1460702_0001641172-25-025702_ex10-1.htm:1]** **[1460702_0001641172-25-025702_ex10-1.htm:2]** 
- The note bears interest at a rate of **18% per annum**, with all accrued interest and the full principal balance due in a single balloon payment on **August 21, 2026**.  **[1460702_0001641172-25-025702_form8-k.htm:1]** **[1460702_0001641172-25-025702_ex10-1.htm:2]** **[1460702_0001641172-25-025702_ex10-1.htm:3]** 
- Marizyme granted Qualigen a security interest in substantially all of its assets, including accounts, equipment, and intellectual property, to secure its obligations under the Amended Note.  **[1460702_0001641172-25-025702_form8-k.htm:1]** **[1460702_0001641172-25-025702_ex10-1.htm:11]** 
- Separately, Qualigen completed a private placement on July 28, 2025, raising net proceeds of **$4,257,937.50** from the sale of Series A-3 Preferred Stock.  **[1460702_0001641172-25-025702_form8-k.htm:2]**

Qualigen Therapeutics (QLGN)